National data and dashboards
Formularies
This dashboard highlights how key kidney medicines are classified on local formularies across the UK, illustrating variation in prescribing responsibilities between primary and specialist care. Covering dapagliflozin, empagliflozin, finerenone, sodium zirconium cyclosilicate (lokelma) and patiromer, the maps show whether medicines are managed in primary care, specialist care, or through shared-care arrangements.
By making regional variation visible, the dashboard helps clinicians, service leads and commissioners understand local prescribing pathways, identify differences in access, and support discussions about the implementation of evidence-based kidney care.
Example dashboard view shown below. Access the interactive map to explore formulary classifications for key kidney medicines by region.
CVD PREVENT for England data
CVD PREVENT brings together routinely available data from England to support improvement in cardiovascular and kidney health. Its dashboard includes several CKD-relevant indicators spanning detection, monitoring, and treatment, allowing users to explore variation at practice, PCN, ICB, and regional level.
These measures help highlight opportunities to improve CKD identification, strengthen routine monitoring (eGFR and urine ACR), and optimise treatment for people at higher kidney and cardiovascular risk — including blood pressure control, renin–angiotensin system blockade, and lipid lowering therapy.
Together, these indicators can support local quality improvement by helping teams understand their current position, identify gaps in care, and track progress over time while more CKD-specific national insight tools are in development.
Relevant indicators are the following:
- CVDP002CKD: Patients whose last two eGFRs are less than 60ml/min/1.73m2 (uncoded CKD), who do not have a record of GP recorded CKD (G3a to G5)
- CVDP003CKD: Patients whose last single eGFR is less than 60ml/min/1.73m2 (at risk of CKD), who do not have a record of GP recorded CKD (G3a to G5)
- CVDP004CKD: Patients with GP recorded CKD (G3a to G5) with a record of a urine ACR test in the preceding 12 months
- CVDP006CKD: Patients with GP recorded CKD (G3a to G5), with a record of an eGFR test in the preceding 12 months.
- CVDP005CKD: Patients with GP recorded CKD (G3a to G5) and hypertension and proteinuria, who are currently treated with renin-angiotensin system antagonists
- CVDP007CKD: Patients with GP recorded CKD (G3a to G5) with an ACR of less than 70 mg/mmol, whose last blood pressure reading is to the appropriate treatment threshold.
- CVDP008CKD: Patients with GP recorded CKD (G3a to G5), who are currently treated with an SGLT2 inhibitor.
- CVDP001CVKM: Patients with GP recorded CKD (G3a to G5), heart failure or type 2 Diabetes Mellitus who are currently treated with an SGLT2 inhibitor.
- CVDP002CVKM: Patients with GP recorded CVD (narrow definition) whose last blood pressure reading is to the appropriate treatment threshold AND whose most recent blood cholesterol level is LDL-cholesterol less than or equal to 2.0 mmol/l or non-HDL cholesterol less than or equal to 2.6 mmol/l, in the preceding 12 months.
- CVDP009HYP: Patients with GP recorded hypertension, with a record of a urine ACR test in the preceding 12 months.
- CVDP010CHOL: Patients with GP recorded chronic kidney disease (G3a to G5), who are currently treated with lipid lowering therapy.
- CVDP002HF: Patients with GP recorded heart failure, with a record of an eGFR test in the preceding 6 months.